Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.52 |
| ▸ | PLIN1 | O60240 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 2/20 | 0.52 |
| ▸ | PLIN5 | Q00G26 | 2/20 | 0.52 |
| ▸ | ABHD5 | Q8WTS1 | 2/20 | 0.52 |
| ▸ | TNKS | O95271 | 1/20 | 0.52 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17331240 | 1.00 | GLA (0.59) | GLATDP1ALDH1A1TSHRLMNA | |
| SCHEMBL560349 | 1.00 | GLA (0.59) | GLATDP1ALDH1A1TSHRLMNA | |
| SCHEMBL8461888 | 0.93 | TDP1 (0.52) | GLATDP1ALDH1A1TSHRLMNA | |
| SCHEMBL8461885 | 0.93 | TDP1 (0.52) | GLATDP1ALDH1A1TSHRLMNA | |
| SCHEMBL10630418 | 0.87 | ALDH1A1 (0.53) | GLATDP1ALDH1A1TSHRLMNA | |
| SCHEMBL10630411 | 0.87 | ALDH1A1 (0.53) | GLATDP1ALDH1A1TSHRLMNA | |
| SCHEMBL23457949 | 0.83 | GLA (0.57) | GLATDP1ALDH1A1TSHRLMNA | |
| SCHEMBL23458032 | 0.83 | GLA (0.57) | GLATDP1ALDH1A1TSHRLMNA | |
| SCHEMBL17331243 | 0.82 | MAPT (0.52) | ALDH1A1LMNAMAPTCYP1A2SMN1; SMN2 | |
| SCHEMBL17331245 | 0.82 | MAPT (0.52) | ALDH1A1LMNAMAPTCYP1A2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9758499-B2 | Stereo controlled synthesis of (E,Z)-dienals via tandem Rh(I) catalyzed propargyl claisen rearrangement | The Florida State University Research Foundation, Inc. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758499-B2 | Stereo controlled synthesis of (E,Z)-dienals via tandem Rh(I) catalyzed propargyl claisen rearrangement | The Florida State University Research Foundation, Inc. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758499-B2 | Stereo controlled synthesis of (E,Z)-dienals via tandem Rh(I) catalyzed propargyl claisen rearrangement | The Florida State University Research Foundation, Inc. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170129865-A1 | STEREO CONTROLLED SYNTHESIS OF (E,Z)-DIENALS VIA TANDEM RH(I) CATALYZED PROPARGYL CLAISEN REARRANGEMENT | The Florida State University Research Foundation, Inc. | 2017-05-11 | — | — | US | disclosed |
| US-20170129865-A1 | STEREO CONTROLLED SYNTHESIS OF (E,Z)-DIENALS VIA TANDEM RH(I) CATALYZED PROPARGYL CLAISEN REARRANGEMENT | The Florida State University Research Foundation, Inc. | 2017-05-11 | — | — | US | disclosed |
| US-20170129865-A1 | STEREO CONTROLLED SYNTHESIS OF (E,Z)-DIENALS VIA TANDEM RH(I) CATALYZED PROPARGYL CLAISEN REARRANGEMENT | The Florida State University Research Foundation, Inc. | 2017-05-11 | — | — | US | disclosed |
| US-9573871-B2 | Stereo controlled synthesis of (E,Z)-dienals via tandem Rh(I) catalyzed propargyl claisen rearrangement | The Florida State University Research Foundation, Inc. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573871-B2 | Stereo controlled synthesis of (E,Z)-dienals via tandem Rh(I) catalyzed propargyl claisen rearrangement | The Florida State University Research Foundation, Inc. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573871-B2 | Stereo controlled synthesis of (E,Z)-dienals via tandem Rh(I) catalyzed propargyl claisen rearrangement | The Florida State University Research Foundation, Inc. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20150361019-A1 | STERO CONTROLLED SYNTHESIS OF (E,Z)-DIENALS VIA TANDEM RH(I) CATALYZED PROPARGYL CLAISEN REARRANGEMENT | The Florida State University Research Foundation, Inc. | 2015-12-17 | — | — | US | disclosed |
| US-20050107348-A1 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC, A DELAWARE LIMITED LIABILITY CORPORATION | 2005-05-19 | — | — | US | disclosed |
| EP-1408946-A4 | HISTONE DEACETYLASE INHIBITORS | CIRCAGEN PHARMACEUTICAL (US) | 2004-06-09 | — | — | EP | disclosed |
| EP-1408946-A2 | HISTONE DEACETYLASE INHIBITORS | Circagen Pharmaceutical (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20030125306-A1 | Histone deacetylase inhibitors | CIRCAGEN PHARMACEUTICAL, A DELAWARE CORPORATION | 2003-07-03 | — | — | US | disclosed |
| US-20030083521-A1 | Such as 5-phenyl-2,4-pentadienoylhydroxamic acid; for treating cancer, hematopoiesis, and genetic metabolic disorders (cystic fibrosis and adrenoleukodystrophy) | CIRCAGEN PHARMACEUTICAL, A MARYLAND CORPORATION | 2003-05-01 | — | — | US | disclosed |
| US-6495719-B2 | FOR USE IN THERAPY OF CANCER, HEMATOLOGICAL DISORDERS, SUCH AS HEMATOPOIESIS, AND GENETIC RELATED METABOLIC DISORDERS, SUCH AS, CYSTIC FIBROSIS AND ADRENOLEUKODYSTROPHY | CIRCAGEN PHARMACEUTICAL | 2002-12-17 | — | — | US | disclosed |
| US-20020143052-A1 | Histone deacetylase inhibitors | ANGELA CHEN SABELLA | 2002-10-03 | — | — | US | disclosed |
| US-20020143196-A1 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC | 2002-10-03 | — | — | US | disclosed |
| WO-2002076941-A2 | HISTONE DEACETYLASE INHIBITORS | CIRCAGEN PHARMACEUTICAL (US) | 2002-10-03 | — | — | WO | disclosed |
| US-20020143037-A1 | Histone deacetylase inhibitors | CIRCAGEN PHARMACEUTICAL, A DELAWARE CORPORATION | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129865-A1 | STEREO CONTROLLED SYNTHESIS OF (E,Z)-DIENALS VIA TANDEM RH(I) CATALYZED PROPARGYL CLAISEN REARRANGEMENT | EPRS1, DHPS, RPL14 | GLA 2980/4885TDP1 4301/4885ALDH1A1 2004/4885 |
| US-20150361019-A1 | STERO CONTROLLED SYNTHESIS OF (E,Z)-DIENALS VIA TANDEM RH(I) CATALYZED PROPARGYL CLAISEN REARRANGEMENT | EPRS1, DHPS, LSS | GLA 3956/4885TDP1 4729/4885ALDH1A1 1870/4885 |
| US-20030083521-A1 | Such as 5-phenyl-2,4-pentadienoylhydroxamic acid; for treating cancer, hematopoiesis, and genetic metabolic disorders (cystic fibrosis and adrenoleukodystrophy) | ZFX, HDAC5, ZNF277 | GLA 1719/4885TDP1 4341/4885ALDH1A1 198/4885 |
| US-20020143052-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC9 | GLA 790/4885TDP1 4043/4885ALDH1A1 474/4885 |
| US-20030125306-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC9 | GLA 790/4885TDP1 4043/4885ALDH1A1 474/4885 |
| US-20020143196-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC5 | GLA 987/4885TDP1 3918/4885ALDH1A1 507/4885 |
| US-20050107348-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC9 | GLA 712/4885TDP1 3951/4885ALDH1A1 374/4885 |
| US-20020143037-A1 | Histone deacetylase inhibitors | HDAC1, HDAC9, HDAC11 | GLA 763/4885TDP1 4231/4885ALDH1A1 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.